Compare MINISO Group Holding Ltd (MNSO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? MINISO Group Holding Ltd trades at $12.46 (market cap $3.87B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 31.5× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.21% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MNSO | VRTX | |
|---|---|---|
Market Cap | $3.87B | $121.95B |
Sector | Technology | Health |
52-Week High | $26.63 | $529.59 |
52-Week Low | $11.30 | $366.54 |
Enterprise Value | $4.54B | $116.69B |
Dividend Yield | 5.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $12.79, up 0.31% today, with a bullish technical signal driven by moving averages. The stock shows strong fundamentals with a P/E of 12.98 and net income margin of 8.98% for 2026. Recent Q1 2026 earnings beat expectations with EPS of $0.591, and the company announced a HK$2 billion share repurchase program on June 29, 2026, signaling confidence.
Outlook is positive given earnings momentum and valuation support, but risks include margin pressure from overseas expansion costs and mixed quarterly performance. Analyst consensus is 75% buy, though one sell rating highlights growth execution concerns. The stock remains a growth play with manageable valuation risks.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
